The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS): Rationale, Design, and Methods
Abstract
Objective The Treatment of Early Onset Schizophrenia Spectrum Disorders Study is a publicly funded clinical trial designed to compare the therapeutic benefits, safety, and tolerability of risperidone, olanzapine, and molindone in youths with early-onset schizophrenia spectrum disorders. The rationale, design, and methods of the Treatment of Early Onset Schizophrenia Spectrum Disorders Study are described. Method Using a randomized, double-blind, parallel-group design at four sites, youths with EOSS (ages 8-19 years) were assigned to an 8-week acute trial of risperidone (0.5-6.0 mg/day), olanzapine (2.5-20 mg/day), or molindone (10-140 mg/day). Responders continued double-blind treatment for 44 weeks. The primary outcome measure was responder status at 8 weeks, defined by a 20% reduction in baseline Positive and Negative Symptom Scale scores plus ratings of significant improvement on the Clinical Global Impressions. Secondary outcome measures included assessments of psychopathology, functional impairment, quality of life, and medication safety. An intent-to-treat analytic plan was used. Results From February 2002 to May 2006, 476 youths were screened, 173 were further evaluated, and 119 were randomized. Several significant study modifications were required to address safety, the use of adjunctive medications, and the termination of the olanzapine treatment arm due to weight gain. Conclusions The Treatment of Early Onset Schizophrenia Spectrum Disorders Study will inform clinic…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The clinical indication for antipsychotics has been also extended to conduct disorders, although with only moderate efficacy rates (31,32).”
From Pediatric psychopharmacology: Too much or too little? (2013) · cites this paper as [31]
Citations
Cites
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378 · cited 3×
“Responder status was defined a priori as a Clinician`s CGI-I (NIMH, 1985) score of 1 (very much improved) or 2 (much improved) plus a 20% reduction in the baseline PANSS score (Kay et al., 1987).”
MethodResultInfluentialEffectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
Self-citationA Children's Global Assessment Scale (CGAS)
Shaffer, D. (1983) · Archives of General Psychiatry · doi:10.1001/archpsyc.1983.01790100074010 · Cited by 3,716
A Rating Scale for Drug-Induced Akathisia
Barnes, T. R. E. (1989) · British Journal of Psychiatry · doi:10.1192/bjp.154.5.672 · Cited by 2,170 · cited 1×
“The Simpson Angus Extrapyramidal Symptom Scale (Simpson and Angus, 1970), the Barnes Akathisia Scales (Barnes, 1989), and the Abnormal Involuntary Movement Scale (National Institute of Mental Health, 1985) were used to monitor EPSEs.”
MethodThe Quality of Life Scale: An Instrument for Rating the Schizophrenic Deficit Syndrome
Heinrichs, D. W., Hanlon, T. E., & Carpenter, W. T. (1984) · Schizophrenia Bulletin · doi:10.1093/schbul/10.3.388 · Cited by 1,688 · cited 1×
“,1984), Child Behavior Checklist-Parent and Teacher versions, Youth Self-Report Form (Achenbach and Rescorla, 2001), the Quality of Life Scale (Heinrichs et al., 1984), and the Caregiver Strain Questionnaire (Brannan et al.”
Autism screening questionnaire: diagnostic validity
Berument, S. K., Rutter, M., Lord, C., Pickles, A., & Bailey, A. (1999) · British Journal of Psychiatry · doi:10.1192/bjp.175.5.444 · Cited by 1,464 · cited 1×
“The Social Communication Questionnaire (Berument et al., 1999) was used to screen for pervasive developmental disorders, given the potential overlap between symptoms of pervasive developmental disorders and negative or prodromal symptoms of schizophrenia.”
MethodDiscovering the Neural Basis of Human Social Anxiety: A Diagnostic and Therapeutic Imperative
Charney, D. S. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.1.1 · Cited by 1,428
Practice Guideline for the Treatment of Patients With Schizophrenia Second Edition
(2007) · APA Practice Guidelines for the Treatment of Psychiatric Disorders: Comprehensive Guidelines and Guideline Watches · doi:10.1176/appi.books.9780890423363.45859 · Cited by 737
Brannan, A. M., Heflinger, C. A., & Bickman, L. (1997) · Journal of Emotional and Behavioral Disorders · doi:10.1177/106342669700500404 · Cited by 452
Childhood-Onset Schizophrenia: A Double-blind Clozapine-Haloperidol Comparison
Kumra, S. (1996) · Archives of General Psychiatry · doi:10.1001/archpsyc.1996.01830120020005 · Cited by 410 · cited 1×
“In two studies of treatment-refractory childhoodonset schizophrenia, clozapine was more beneficial than haloperidol for positive and negative symptoms (n = 21; Kumra et al., 1996) and superior to olanzapine for negative symptoms (n = 25; Shaw et al.”
Background
Research works printed but not linked: 3
- Kryzhanovskaya, 2006, A double-blind, placebo-controlled study of olanzapine in adolescents with schizophrenia, Schizophr Res, 81, S44
- National Institute of Mental Health, 1985, Special feature: rating scales and assessment instruments for use in pediatric psychopharmacology research, Psychopharmacol Bull, 21, 765
- Simpson, 1970, A rating scale for extrapyramidal effects, Acta Psychiatr Scand, 212, 111
Cited by
Sikich, L., Frazier, J. A., McClellan, J., Findling, R. L., Vitiello, B., Ritz, L., Ambler, D., Puglia, M., Maloney, A. E., Michael, E., et al. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08050756 · Cited by 478
“Concomitant treatments with anticholinergic agents, propranolol, and benzodiazepines were guided by algorithms (28).”
InfluentialSelf-citationKumra, S., Oberstar, J. V., Sikich, L., Findling, R. L., McClellan, J. M., Vinogradov, S., & Charles Schulz, S. (2007) · Schizophrenia Bulletin · doi:10.1093/schbul/sbm109 · Cited by 186
Self-citationMcIntyre, R. S., & Jerrell, J. M. (2008) · Archives of Pediatrics & Adolescent Medicine · doi:10.1001/archpedi.162.10.929 · Cited by 178
Goldstein, T. R., Fersch-Podrat, R. K., Rivera, M., Axelson, D. A., Merranko, J., Yu, H., Brent, D. A., & Birmaher, B. (2015) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2013.0145 · Cited by 166
“Guidelines for the treatment of BP in youth identify both pharmacotherapy and psychotherapy as important components of optimal treatment (McClellan et al. 2007).”
BackgroundKryzhanovskaya, L., Schulz, S. C., Mcdougle, C., Frazier, J., Dittmann, R., Robertson-Plouch, C., Bauer, T., Xu, W., Wang, W., Carlson, J., et al. (2009) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e3181900404 · Cited by 168
Self-citation
Metadata
- Authors
- McCLELLAN, J., SIKICH, L., FINDLING, R. L., FRAZIER, J. A., VITIELLO, B., HLASTALA, S. A., WILLIAMS, E., AMBLER, D., HUNT-HARRISON, T., MALONEY, A. E., RITZ, L., ANDERSON, R., HAMER, R. M., & LIEBERMAN, J. A.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- McCLELLAN, JON
- ORCID
- Venue
- Journal of the American Academy of Child & Adolescent Psychiatry
- Publisher
- Elsevier BV
- Published
- 2007-08
- Volume
- 46
- Issue
- 8
- Pages
- 969-978
- ISSN
- 0890-8567 (ISSN-L)
- OpenAlex
- W2048486175
- Cited by
- 90
- References
- 37
- Citations by year
- 2026: 2 · 2024: 1 · 2023: 1 · 2020: 1 · 2019: 1 · 2018: 1 · 2017: 2 · 2016: 3 · 2015: 4 · 2014: 5 · 2013: 5 · 2012: 6
- FWCI
- 10.09
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- Journal of the American Academy of Child & Adolescent Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- The Journal of the American Medical Association (JAMA) Network (American Medical Association) (submittedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Funders
- National Institute of Mental Health (U01MH062726, K23 MH70570, U01 MH62726, U01MH061355, U01MH61355, K23MH070570, U01MH061528, U01MH061464, U01MH61528, U01MH61464)
- National Center for Research Resources (M01 RR00046, M01-RR 00037, M01RR000046, M01RR000037)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Keywords
- antipsychotic drugs, risperidone, olanzapine, molindone, drug safety, suicidality, weight gain, adolescent psychiatry, treatment response, functional disability, quality of life
- MeSH terms
- Olanzapine, Adolescent, Adult, Benzodiazepines, Child, Depressive Disorder, Major, Major Depressive Disorder, Double-Blind Method, Female, Humans, Male, Molindone, Schizophrenia, Time Factors, Antipsychotic Agents, Comorbidity, Age of Onset, Risperidone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS): Rationale, Design, and Methods. https://app.cochat.ai/papers/10.1097/chi.0b013e3180691779
- The paper
- McCLELLAN, J., SIKICH, L., FINDLING, R. L., FRAZIER, J. A., VITIELLO, B., HLASTALA, S. A., WILLIAMS, E., AMBLER, D., HUNT-HARRISON, T., MALONEY, A. E., RITZ, L., ANDERSON, R., HAMER, R. M., & LIEBERMAN, J. A. (2007). Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS): Rationale, Design, and Methods. Journal of the American Academy of Child & Adolescent Psychiatry. https://doi.org/10.1097/chi.0b013e3180691779
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.